NCT06477783Recruiting
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Prospective Observational Study on the Clinical Efficacy of Teclistamab and Talquetamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
The aim of this study is to assess the clinical efficacy of the anti-BCMA/CD3 bispecific antibody teclistamab and anti-GPRC5D/CD3 bispecific antibody talquetamab in a prospective, real-life setting in Belgium.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 14 May 2024
- Start date
- 1 Dec 2024
- Primary completion date
- Sept 2027
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Multiple myeloma
- NCT number
- NCT06477783
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Dec 2024 to the primary completion date, Sept 2027
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has started teclistamab or talquetamab treatment \>28 days before intended screening visit.
Other
- Inability or unwillingness to comply with the study protocol, including scheduled visits, treatment plans, or follow-up requirements.
Who the study is looking for
- Age 18 years or older
- Written informed consent
- Has a diagnosis of relapsed and refractory multiple myeloma
- Has already received at least three previous treatments
- Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody
- Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria
- Anticipated to start treatment with teclistamab or talquetamab per routine clinical care or has started with teclistamab treatment ≤28 days before intended screening visit
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Imelda Coordinator of this site? Confirm its status | Bonheiden | Belgium | Not yet recruiting |
| Institut Jules Bordet Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
| UCL - Saint Luc Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
| Grand Hopital de Charleroi Coordinator of this site? Confirm its status | Charleroi | Belgium | Recruiting |
| Universitair Ziekenhuis Antwerpen (Uza) Coordinator of this site? Confirm its status | Edegem | Belgium | Recruiting |
| Universitair Ziekenhuis Gent (Uz Gent) Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
| Algemeen Ziekenhuis Maria Middelares (AZMM) Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
| JESSA Ziekenhuis Coordinator of this site? Confirm its status | Hasselt | Belgium | Recruiting |
| Epicura Coordinator of this site? Confirm its status | Hornu | Belgium | Recruiting |
| AZ Groeninge Coordinator of this site? Confirm its status | Kortrijk | Belgium | Recruiting |
| UZ Leuven Gasthuisberg Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| CHU Liège Coordinator of this site? Confirm its status | Liège | Belgium | Recruiting |
| CHR Citadelle Coordinator of this site? Confirm its status | Liège | Belgium | Recruiting |
| CHU Ambroise Paré Coordinator of this site? Confirm its status | Mons | Belgium | Recruiting |
| AZ Delta Coordinator of this site? Confirm its status | Roeselare | Belgium | Recruiting |
| Vitaz Coordinator of this site? Confirm its status | Sint-Niklaas | Belgium | Recruiting |
| Chu Ucl Namur Coordinator of this site? Confirm its status | Yvoir | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.